When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
KTOV - Kitov to conduct Phase 1/2 NT219 trial in advanced cancer patients
Kitov Pharma Ltd.
The FDA has accepted Kitov Pharma's (NASDAQ:KTOV) Investigational New Drug application to conduct a Phase 1/2 clinical trial of NT219, a novel agent addressing treatment resistance in advanced cancer.
More news on: Kitov Pharma Ltd, Healthcare stocks news, Stocks on the move,